Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus

被引：41

作者：

Jinnouchi, Hideaki ^{[1
,2
,3
]}

Sugiyama, Seigo ^{[1
,3
,4
]}

Yoshida, Akira ^{[1
]}

Hieshima, Kunio ^{[1
]}

Kurinami, Noboru ^{[1
]}

Suzuki, Tomoko ^{[1
]}

Miyamoto, Fumio ^{[1
]}

Kajiwara, Keizo ^{[1
]}

Matsui, Kunihiko ^{[5
]}

Jinnouchi, Tomio ^{[1
,3
]}

机构：

[1] Jinnouchi Hosp, Diabet Care Ctr, Chuo Ku, Kumamoto 8620976, Japan

[2] Kumamoto Univ Hosp, Dept Cardiovasc Med, Div Prevent Cardiol, Chuo Ku, Kumamoto 8608556, Japan

[3] Jinnouchi Hosp, Div Cardiovasc, Diabet Care Ctr, Chuo Ku, Kumamoto 8620976, Japan

[4] Kumamoto Univ, Grad Sch Med Sci, Fac Life Sci, Dept Cardiovasc Med,Chuo Ku, Kumamoto 8608556, Japan

[5] Kumamoto Univ Hosp, Dept Community Med, Chuo Ku, Kumamoto 8608556, Japan

来源：

JOURNAL OF DIABETES RESEARCH | 2015年 / 2015卷

关键词：

BETA-CELL FUNCTION; INCRETIN-BASED THERAPIES; RECEPTOR AGONISTS; OXIDATIVE STRESS; MOUSE MODEL; INFLAMMATION; DYSFUNCTION; GLYCEMIA; NN2211;

D O I：

10.1155/2015/706416

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aims. Glucagon-like peptide-1 (GLP-1) analog promotes insulin secretion by acting on pancreatic beta-cells. This antihyperglycemic treatment for type 2 diabetes mellitus (DM) has attracted increased clinical attention not only for its antihyperglycemic action but also for its potential extrapancreatic effects. We investigated whether liraglutide, a GLP-1 analog, could enhance insulin sensitivity as assessed by the hyperinsulinemic-euglycemic clamp in type 2 DM patients. Materials. We prospectively enrolled 31 uncontrolled type 2 DM patients who were hospitalized and equally managed by guided diet-and exercise-therapies and then introduced to either liraglutide- or intensive insulin-therapy for 4 weeks. Insulin sensitivity was assessed by the glucose infusion rate (GIR) using hyperinsulinemic-euglycemic clamp before and after the therapies. Results. Values of HbA1c, postprandial plasma glucose, and body mass index (BMI) were significantly decreased by hospitalized intensive insulin-therapy or liraglutide-therapy. GIR was significantly increased by liraglutide-therapy but not by insulin-therapy, indicating that liraglutide-therapy significantly enhanced insulin sensitivity. BMI decreased during liraglutide-therapy but was not significantly correlated with changes in GIR. Multivariate logistic regression analysis demonstrated that liraglutide-therapy significantly correlated with increased insulin sensitivity in uncontrolled DMpatients. Conclusions. Liraglutide may exhibit favorable effects on diabetes control for type 2 DMpatients by increasing insulin sensitivity as an extrapancreatic action.

引用

页数：8

共 28 条

[1] One-year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients A randomized, controlled trial [J].